Overview of COVID-19 Therapeutics and Prophylaxis for non-hospitalized patients.

The resources below provide:
  1. Interim guidance on outpatient treatment decisions for patients at risk of developing severe COVID-19.
  2. Comparison table of treatment options.
  3. How providers may obtain these treatments or prophylaxis for their patients.
  4. Where providers can refer their patients for infusion therapies.
  5. Reporting requirements.

Treatment Guidelines:
NIH Therapeutic Management of Nonhospitalized Adults 

The FDA has suspended distribution of sotrovimab due to the omicron BA.2 subvariant, which now accounts for more than half of COVID-19 infections.  Bebtilovimab is now the preferred monoclonal antibody therapy.

Responsive Image

Treatment

Responsive Image
*Adapted from COCA call 1/22/22
Clinicians should refer to the EUA healthcare provider fact sheets for further details on Paxlovidsotrovimabbebtelovimab, remdesivir, and molnupiravir. For the FDA-approved remdesivir (Veklury) for 12 yrs and older weight at least 40kg, refer to the full prescribing information.

Prophylaxis

Evusheld
Description
  • Evusheld is a monoclonal antibody combination approved for use as a Pre-exposure Prophylaxis for those who are unable to receive or are not expected to mount an immune response with vaccines.
  • Distribution should be prioritized to hospitals that offer special services such as oncology and rheumatology, etc. Providers who care for such patients should refer to these centers for access to this product.
Patient Profiles
  • Active treatment for solid tumor and hematologic malignancies
  • Receipt of solid-organ transplant and taking immunosuppressive therapy
  • Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within two years of transplantation or taking immunosuppression therapy)
  • Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
  • Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm3, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)
  • Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents).

Become a Provider

HHS currently distributes an allocation of Bebtelovimab, Paxlovid, Molnupiravir, and Evusheld to each state. All medications must be ordered through the Health Partners Order Portal (HPOP). 
 
  1. Sign up with HPOP here.
  2. If you need help getting set up, email DPH.MABTherapy@illinois.gov

Locate Therapeutics and Prophylaxis in the City

  • Infusion Providers Accepting External Referrals:
Provider
Contact Information:
AMITA Health Saints Mary and Elizabeth Medical Center Tel: 312-770-8534
Fax: 312-770-3182
John H Stroger Jr Hospital of Cook County covidtherapeutics@cookcountyhhs.org
Provident Hospital of Chicago covidtherapeutics@cookcountyhhs.org
Saint Anthony Hospital ttruesdell@sahchicago.org
Swedish Covenant Hospital Tel: 773-907-7700
  • Test to Treat in Chicago
  • Providers who don’t want to receive allocations can use the ASPR COVID-19 Therapeutics Locator to find providers, pharmacies and infusion centers with doses on hand. 
  • For providers looking for immediate access to COVID-19 Therapeutics, available doses may be found on the IDPH Matchmaker Site. If you are a provider and have extra doses in between distribution cycles, please use this site so others have access. 

State and Federal Reporting Requirements

  • Weekly reporting on the use of federally purchased COVID-19 therapeutics is required each Wednesday by 11:59 pm ET
  • All site administering these therapies must report product utilization and stock on hand.
  • For sites reporting for the first time, report the quantity of product on hand and utilization TO DATE since the facility started providing the therapies. All subsequent reporting cycles must be based on weekly utilization. 
  • For more information on reporting for specific sites, please visit the HHS Reporting Utilization of COVID Therapeutics webpage.
Responsive Image

CHI COVID Rx Reporting

Pursuant to Health Order No. 2020-4 sites administering USG-Purchased COVID-19 therapeutics in the City of Chicago must report individual level utilization data.

Click here to visit the portal and share your therapeutics data with us. 

For questions about reporting or data requirements, please view the FAQ or contact Frances Lendacki at frances.lendacki@cityofchicago.org

Sites interested in providing USG-purchased COVID-19 therapeutics can request access to the Health Partner Order Portal (HPOP) here.